Notably, this interplay between MYC and HIF factors in ccRCC tumors may have important ramifications for treatment selection, as tumors from patients that have high levels of MYC and HIF-2α protein are more likely to be refractory to the anti-angiogenic drug sunitinib. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.